Holen Sie sich die Stockscreener-App
1.83
3.10%
0.055
Handel nachbörslich:
1.83
Schlusskurs vom Vortag:
$1.775
Offen:
$1.77
24-Stunden-Volumen:
50,282
Relative Volume:
0.93
Marktkapitalisierung:
$3.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.69%
1M Leistung:
-8.50%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.75
$1.83
1-Wochen-Bereich:
$1.68
$2.06
52-Wochen-Spanne:
$1.6313
$2.20
Vivosim Labs Inc Stock (VIVS) Company Profile
Firmenname
Vivosim Labs Inc
Sektor
Branche
Telefon
858-224-1000
Adresse
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie VIVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.83 | 3.46M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-12-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-11-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | Eingeleitet | Raymond James | Outperform |
| 2015-08-11 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | Eingeleitet | Jefferies | Buy |
| 2015-06-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Vivosim Labs Inc Aktie (VIVS) Neueste Nachrichten
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - The Globe and Mail
Analytical Overview: VivoSim Labs Inc (VIVS)’s Ratios Tell a Financial Story - DWinneX
VivoSim Labs (VIVS) Unveils NAMkind Platform with Leading Predictive Capabilities | VIVS Stock News - GuruFocus
VivoSim Labs, Inc. Showcases NAMkind™ Platform's Industry-Leading Liver Toxicology Prediction at Digestive Disease Week Conference - Nasdaq
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - TradingView
VivoSim Labs regains Nasdaq compliance By Investing.com - Investing.com Nigeria
VivoSim Labs regains Nasdaq compliance - Investing.com
VivoSim Labs Avoids Nasdaq Delisting with Compliance Plan - TipRanks
Organovo Holdings, Inc. Announces Board Appointments - marketscreener.com
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - marketscreener.com
Organovo: Fiscal Q2 Earnings Snapshot - marketscreener.com
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents - marketscreener.com
VivoSim Labs introduces AI-driven drug testing models By Investing.com - Investing.com Canada
VIVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Two new option listings and one option delisting on April 24th - TipRanks
VivoSim Announces Emergence from Stealth Mode To Provide Technol - GuruFocus
VivoSim Labs introduces AI-driven drug testing models - Investing.com Australia
VIVS Stock Price and Chart — NASDAQ:VIVS - TradingView
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - The Manila Times
VivoSim Labs, Inc. Emerges from Stealth Mode to Revolutionize Drug Discovery with Non-Animal Toxicology Models Following FDA Initiative - Nasdaq
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from - Bluefield Daily Telegraph
FDA Shift Powers VivoSim's Game-Changing Drug Testing Tech: 50% Cost Reduction Target - Stock Titan
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' - GuruFocus
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' | ONVO Stock News - GuruFocus
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech - TipRanks
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
VivoSim to Carry Forward Organovo 3D Bioprinting | ONVO Stock Ne - GuruFocus
Organovo Holdings Announces Transition to VivoSim Labs - TipRanks
VivoSim to Carry Forward Organovo 3D Bioprinting - The Manila Times
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation - Stock Titan
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo'S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company - marketscreener.com
Eli Lilly and Company entered into an asset purchase agreement to acquire FXR Program and Related Assets of Organovo Holdings, Inc. for $60 million. - marketscreener.com
ONVO Stock Quote Price and Forecast - CNN
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings - marketscreener.com
ORGANOVO HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Organovo Holdings, Inc. Announces Executive Changes - marketscreener.com
ONVOOrganovo Holding Latest Stock News & Market Updates - Stock Titan
Imagine Owning Organovo Holdings (NASDAQ:ONVO) And Trying To Stomach The 82% Share Price Drop - simplywall.st
Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga (NASDAQ:VIVS) - Seeking Alpha
Finanzdaten der Vivosim Labs Inc-Aktie (VIVS)
Es liegen keine Finanzdaten für Vivosim Labs Inc (VIVS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):